A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4 + and CD8 + T-cell as well as B-cell responses

Cancer Immunology, Immunotherapy

Volumn 60, Issue 9, 2011, Pages 1333-1346

  Neumann, Frank ^a   Kubuschok, Boris ^a   Ertan, Kubilay ^b   Schormann, Claudia ^a   Stevanovic, Stefan ^c   Preuss, Klaus Dieter ^a   Schmidt, Werner ^a   Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Department of Gynecology and Obstetrics   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

B cell epitope; Cancer testis antigen; CD4 + T cell epitope; CD8 + T cell epitope; SSX2; Tumor immunology

Indexed keywords

ANTIBODY; CANCER TESTIS ANTIGEN; CANCER VACCINE; EPITOPE; HLA DR ANTIGEN; HOM MEL 40 SSX2; PEPTIDE; SSX2 ANTIBODY; SSX2 P 101 111; UNCLASSIFIED DRUG;

ALGORITHM; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; BLOOD CELL; CANCER IMMUNIZATION; CANCER PATIENT; CAUCASIAN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; NEOPLASM; PREDICTION; PRIORITY JOURNAL; TUMOR IMMUNITY;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; B-LYMPHOCYTES; CANCER VACCINES; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HLA-DR ANTIGENS; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASMS; PEPTIDE FRAGMENTS; REPRESSOR PROTEINS;

EID: 80054681186     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1030-6     Document Type: Article

References (25)

1. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S et al (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914-1918 (Pubitemid 27113936)
2. + cytolytic T lymphocytes. Cancer Res 60:6272-6275
3. Preuss KD, Zwick C, Bormann C, Neumann F, Pfreundschuh M (2002) Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 188:43-50 (Pubitemid 35398864)
4. Clark J, Rocques PJ, Crew AJ, Gill S, Shipley J, Chan AM et al (1994) Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 7:502-508 (Pubitemid 24308337)
5. Tureci O, Chen YT, Sahin U, Gure AO, Zwick C, Villena C et al (1998) Expression of SSX genes in human tumors. Int J Cancer 77:19-23 (Pubitemid 28308546)
6. Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D et al (2002) Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol 168:1717-1722 (Pubitemid 34135769)
7. Wagner C, Neumann F, Kubuschok B, Regitz E, Mischo A, Stevanovic S et al (2003) Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2. Cancer Immun 3:18
8. Neumann F, Wagner C, Stevanovic S, Kubuschok B, Schormann C, Mischo A et al (2004) Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2. Int J Cancer 112:661-668 (Pubitemid 39425947)
9. Ayyoub M, Merlo A, Hesdorffer CS, Speiser D, Rimoldi D, Cerottini JC et al (2005) Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2. Clin Immunol 114:70-78 (Pubitemid 39642792)
10. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D et al (2007) Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 104:8947-8952 (Pubitemid 47175417)
11. Tureci O, Sahin U, Schobert I, Koslowski M, Schmitt H, Schild HJ et al (1996) The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res 56:4766-4772 (Pubitemid 26338082)
12. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A et al (1994) Development of high potency universal DR-restricted helper epitopes by modification of high affinity DRblocking peptides. Immunity 1:751-761
13. Lang KS, Moris A, Gouttefangeas C, Walter S, Teichgraber V, Miller M et al (2002) High frequency of human cytomegalovirus (HCMV)-specific CD8 + T cells detected in a healthy CMV-seropositive donor. Cell Mol Life Sci 59:1076-1080 (Pubitemid 34734638)
14. Chen YT, Stockert E, Chen Y, Garin-Chesa P, Rettig WJ, van der Bruggen P et al (1994) Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci USA 91:1004-1008 (Pubitemid 24048497)
15. Neumann F, Wagner C, Preuss KD, Kubuschok B, Schormann C, Stevanovic S et al (2005) Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells. Blood 106:3105-3113 (Pubitemid 41565907)
16. zum Buschenfelde CM, Metzger J, Hermann C, Nicklisch N, Peschel C, Bernhard H (2001) The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J Immunol 167:1712-1719 (Pubitemid 32703174)
17. Utz U, Banks D, Jacobson S, Biddison WE (1996) Analysis of the T-cell receptor repertoire of human T-cell leukemia virus type 1 (HTLV-1) Tax-specific CD8 + cytotoxic T lymphocytes from patients with HTLV-1-associated disease: evidence for oligoclonal expansion. J Virol 70:843-851
18. Kubuschok B, Schmits R, Hartmann F, Cochlovius C, Breit R, Konig J et al (2002) Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model. Hum Gene Ther 13:815-827 (Pubitemid 34493975)
19. Mischo A, Wadle A, Watzig K, Jager D, Stockert E, Santiago D et al (2003) Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients. Cancer Immun 3:5
20. Preuss KD, Regitz E, Neumann F, Pfreundschuh M (2006) B-cell epitopes from the cancer testis antigen NY-ESO-1. Int J Cancer 118:253 (Pubitemid 41681607)
21. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-712
22. Mischo A, Kubuschok B, Ertan K, Preuss KD, Romeike B, Regitz E et al (2006) Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer 118:696-703 (Pubitemid 43076020)
23. Zeng G, Li Y, El Gamil M, Sidney J, Sette A, Wang RF et al (2002) Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res 62:3630-3635 (Pubitemid 34728837)
24. van den Broek M, von Boehmer L, Knuth A (2010) Developments in cancer immunotherapy. Dig Dis 28:51-56
25. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW et al (2007) Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA 104:12837-12842 (Pubitemid 47255241)